Patient characteristics and ophthalmic data of control and diabetic retinopathy patients (e.g., a, b, etc.)
M/FAgeDiagnosisLateralityUnderlying diseasesBCVAIOPSECMTHbA1c
Control
 1F66ControlOD(−)0.420errn/cn/c
 2M62ControlOD(−)1131228n/c
 3F67ControlOD(−)0.3130n/cn/c
PDR
 4M50NVG, HRPDROSDM, HTN, CKD0.519−2.52106.6
 5M56PDRODDM, HTN, CKD0.515−1.752328.4
 6M62HRPDR,VHODDM, HTN, CKD0.151702807.7
 7M33NVG, HRPDR,VHOSDMFC30 cm62−2.752248.4
 8M25HRPDRODDM0.0417errn/ca13.1
 9F44HRPDROSDM, HTN, CKD0.220−2.2526311.7
 10F52HRPDROSDM, HTN, CKDFC40 cm16−1.252657.3

aNot checkable due to premacular hemorrhage.

BCVA, best corrected visual acuity; CKD, Chronic kidney disease; CMT, central macular thickness; DM, diabetes mellitus; DME, diabetic macular edema; HbA1c, hemoglobin A1c; HRPDR, high risk proliferative diabetic retinopathy; HTN, hypertension; IOP, intraocular pressure; NVG, neovascular glaucoma; PDR, proliferative diabetic retinopathy; SE, spherical equivalent; VH, vitreous hemorrhage.

Exp Neurobiol 2018;27:238~244 https://doi.org/10.5607/en.2018.27.3.238
© Exp Neurobiol